Has Jeremy Pollock, MD received payments from drug or device companies?

Yes. Drug and device makers reported $80,073 in general payments to Jeremy Pollock, MD across 558 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeremy Pollock, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeremy Pollock, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeremy Pollock, MD

Cardiovascular Disease · Towson, MDNPI 1124310289

Payments from drug & device makers

$80,073in general payments, 2019–2025

Across 558 payments — averaging $143.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$43K
Amarin Pharma, Inc.$21K
Scpharmaceuticals Inc.$4K
Lilly USA, LLC$3K
Medtronic$1K
Pfizer$1K
plus $7K from 34 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	76	$42,898
Amarin Pharma, Inc.	31	$20,580
Scpharmaceuticals Inc.	9	$4,413
Lilly USA, LLC	6	$2,865
Medtronic	22	$1,156
Pfizer	71	$1,084
Edwards Lifesciences	13	$944
Novartis	49	$787
E.r. Squibb & Sons, L.L.C.	49	$741
Amgen	36	$711
Johnson & Johnson	36	$546
AstraZeneca	32	$500
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	16	$294
Novo Nordisk	13	$271
Esperion Therapeutics, Inc.	13	$225
Alnylam Pharmaceuticals Inc.	8	$219
Abbott	5	$181
Sanofi-aventis U.S. LLC	9	$176
Atricure, Inc.	6	$173
Actelion Pharmaceuticals US, Inc.	7	$160
Preventice Services, LLC	1	$132
Irhythm Technologies, Inc.	7	$118
Kiniksa Pharmaceuticals, Ltd.	5	$97
Philips North America LLC	4	$93
Regeneron Healthcare Solutions, Inc.	6	$91
Kiniksa Pharmaceuticals International, PLC	4	$78
Lexicon Pharmaceuticals, Inc.	3	$66
Kestra Medical Technology Services, Inc.	1	$63
Boston Scientific	2	$61
Gilead	4	$59
Merck	3	$59
Kowa Pharmaceuticals America, Inc.	3	$40
Braemar Manufacturing, LLC	1	$36
Bardy Diagnostics, Inc.	1	$34
Cardiva Medical, Inc.	1	$29
Chiesi USA, Inc.	1	$22
Bayer	1	$21
Lantheus Medical Imaging, Inc.	1	$20
Biotronik Inc.	1	$16
Elutia, Inc.	1	$15

How this compares

$80,073 in reported general payments places this provider in the 90th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland →

Medicare billing

Part B allowed, 2024

$506,993

Medicare patients

2,735

Services billed

8,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Towson

Christopher DefilippiBaltimore$9.2M
Thorsten LeuckerBaltimore$7.1M
Joao LimaBaltimore$5.6M
Jeffrey ColeBaltimore$4.8M
Carlos InceBaltimore$3M
Paul GurbelBaltimore$2.6M
Navin KapurBaltimore$1.8M
Vineet VenugopalLanham$1.5M
Robert WeissBaltimore$1.4M
Stephen GottliebBaltimore$1.4M

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →